NMPA Seeks Public Comments on the Revised "Measures for the Supervision and Administration of Medical Device Online Sales" (Draft for Comments)

To further strengthen the supervision of medical device online sales and safeguard public medical device safety, the National Medical Products Administration (NMPA) has organized the revision of the "Measures for the Supervision and Administration of Medical Device Online Sales" and drafted the revised version (Draft for Comments), which was officially released for public comment on July 27, 2026.

The revised draft consists of 6 chapters and 64 articles, covering General Provisions, Medical Device Online Sales, Medical Device E-commerce Platform Services, Supervision and Inspection, Legal Liability, and Supplementary Provisions. Key highlights include strengthened quality management system requirements for online sellers, clarified filing and regulatory obligations for medical device e-commerce platform operators, and specific provisions for the rapidly growing live-streaming marketing of medical devices—stipulating that live-streaming room operators must possess legitimate qualifications, livestreamers must be employees of the enterprise, and Class III medical devices as well as devices designated for hospital use only shall not be marketed via live-streaming.

The public comment period runs from July 27, 2026 to August 26, 2026.Interested parties and individuals may submit their feedback via the Opinion Suggestion Form (Appendix 2) to: qxjgec@nmpa.gov.cn, with the email subject line stating "Feedback on the Measures for the Supervision and Administration of Medical Device Online Sales".

This revision represents a significant update to the 2017 original measures, addressing new developments and challenges in the medical device online sales landscape.